XML 49 R22.htm IDEA: XBRL DOCUMENT v3.19.3
Collaborative Arrangements and Licensing Agreements (Tables)
9 Months Ended
Sep. 30, 2019
Biogen [Member]  
Collaborative Arrangements and Licensing Agreements [Abstract]  
Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2019 and 2018, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):


 
Three Months Ended
September 30,
   
Nine Months Ended
September 30,
 
   
2019
   
2018
   
2019
   
2018
 
SPINRAZA royalties (commercial revenue)
 
$
81.7
   
$
70.0
   
$
211.9
   
$
167.7
 
R&D revenue
   
25.5
     
34.8
     
81.9
     
66.9
 
Total revenue from our relationship with Biogen
 
$
107.2
   
$
104.8
   
$
293.8
   
$
234.6
 
Percentage of total revenue
   
64
%
   
72
%
   
47
%
   
58
%
GSK [Member]  
Collaborative Arrangements and Licensing Agreements [Abstract]  
Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2019 and 2018, we earned the following revenue from our relationship with GSK (in millions, except percentage amounts):


 
Three Months Ended
September 30,
   
Nine Months Ended
September 30,
 
   
2019
   
2018
   
2019
   
2018
 
R&D revenue
 
$
25.1
   
$
0.1
   
$
25.3
   
$
1.5
 
Percentage of total revenue
   
15
%
   
0
%
   
4
%
   
0
%
Roche [Member]  
Collaborative Arrangements and Licensing Agreements [Abstract]  
Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2019 and 2018, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):


 
Three Months Ended
September 30,
   
Nine Months Ended
September 30,
 
   
2019
   
2018
   
2019
   
2018
 
R&D revenue
 
$
4.7
   
$
1.8
   
$
52.3
   
$
5.4
 
Percentage of total revenue
   
3
%
   
1
%
   
8
%
   
1
%
Novartis [Member]  
Collaborative Arrangements and Licensing Agreements [Abstract]  
Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2019 and 2018, we earned the following revenue from our relationship with Novartis (in millions, except percentage amounts):


 
Three Months Ended
September 30,
   
Nine Months Ended
September 30,
 
   
2019
   
2018
   
2019
   
2018
 
R&D revenue
 
$
8.5
   
$
7.2
   
$
176.3
   
$
42.7
 
Percentage of total revenue
   
5
%
   
5
%
   
28
%
   
10
%